SCHEMBL7455329

SCHEMBL7455329

CC(C)(C)OC(=O)Nc1conc1C(=O)NC1CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.45
LMNA P02545 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ALPL P05186 1/20 0.39
ALPI P09923 1/20 0.39
ALPG P10696 1/20 0.39
METAP1 P53582 1/20 0.38
KDM1A O60341 1/20 0.38
MAOB P27338 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
EPHX1 P07099 1/20 0.38
DRD2 P14416 3/20 0.36
GAA P10253 2/20 0.36
HDAC4 P56524 2/20 0.35
PBK Q96KB5 1/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
BTK Q06187 1/20 0.34
TRPV1 Q8NER1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7456798 0.88 PDE10A (0.37) PDE10ALMNASMN1; SMN2ALPLALPI
SCHEMBL26921836 0.80 METAP1 (0.38) METAP1GAA
SCHEMBL7456808 0.76 SMN1; SMN2 (0.46) LMNASMN1; SMN2KDM1AMAOBEPHX1
SCHEMBL26921777 0.74 ALDH1A1 (0.39) SMN1; SMN2METAP1
SCHEMBL16814041 0.74 BRD9 (0.38) METAP1
SCHEMBL3336547 0.73 PKM (0.57) LMNAKDM1AMAOBL3MBTL1
SCHEMBL19914395 0.72 KDM1A (0.40) SMN1; SMN2ALPLALPIALPGKDM1A
SCHEMBL19914396 0.70 LCK (0.44) LMNA
SCHEMBL3667398 0.69 NAMPT (0.54) SMN1; SMN2KDM1AMAOBEPHX1
SCHEMBL7454390 0.69 HIF1A (0.43) PDE10ASMN1; SMN2TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2580207-B1 NITROGEN CONTAINING HETEROARYL COMPOUNDS HOFFMANN LA ROCHE (CH) 2017-09-27 EP disclosed
US-8703768-B2 Nitrogen containing heteroaryl compounds HOFFMANN-LA ROCHE INC. (US) 2014-04-22 US disclosed
US-8623866-B2 2014-01-07 US disclosed
EP-2580207-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2013-04-17 EP disclosed
WO-2011154327-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2011-12-15 WO disclosed
US-20110306589-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2011-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110306589-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS PDE10A, PDE3A, PDE2A PDE10A 1/4885LMNA 2125/4885SMN1; SMN2 1370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.